Iomeprol
Small moleculeapproved
Approved
Nov 27, 2024
Clinical trial activity
4 trials · 4 clinical orgs · 1 marketing orgs
Phase 1
0
Phase 2
1
Phase 3
1
Phase 4
2
Earliest trial started Nov 1, 2004 (NCT00165620)
Timeline
Indications
Approved for
Mechanism of action
- Unspecified targetOTHER
Diagnostic
- Unspecified targetContrast agent
contrast agent
Approval history
- approvedNov 27, 2024
Chemistry & pharmacology
Loading structure…
SMILES
CN(C(=O)CO)c1c(I)c(C(=O)NCC(O)CO)c(I)c(C(=O)NCC(O)CO)c1I- Mol. weight
- 777.09 g/mol
- Lipinski Ro5
- 2 violation(s)
- Rule of 3
- No
- Chirality
- Racemic Mixture
- Inorganic
- No
- Polymer
- No
- Delivery
- Parenteral
- Availability
- Prescription Only
Oral
No
Parenteral
Yes
Topical
No
Sources
- ChEMBLCHEMBL2107214 ↗
Also known as
- e7337
- imeron
- imeron
- iomeprol
- iomeprol
- iomeprol
- iomeprol
- iomeprol
- iomeprol
- iomeprol
- iomeprol
- iomeprol 350
- iomeprol 400
- iomeron
- iomeron
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT01255722 | Phase 4 | Nov 1, 2010 | Guerbet, Kantonsspital Lucerne |
| NCT00390585 | Phase 4 | Jul 1, 2006 | Technical University of Munich |
| NCT00280410 | Phase 2/Phase 3 (Phase 3) | Feb 1, 2006 | Eisai |
| NCT00165620 | Phase 2 | Nov 1, 2004 | Eisai |
Showing 4 of 4 trials
Page 1 / 1
Organizations
Research & Development (4)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Eisai | For profit | 2 | 2 | 2 | 2004 |
| Guerbet | For profit | 1 | 1 | 1 | 2010 |
| Kantonsspital Lucerne | Academic/Hospital | 1 | 0 | 1 | 2010 |
| Technical University of Munich | Academic/Hospital | 1 | 1 | 1 | 2006 |
4 organizations
Page 1 / 1
Marketing (1)
| Organization | Org type | Relationship | Date |
|---|---|---|---|
| Bracco | For profit | NDA | Nov 27, 2024 |